重组人脑利钠肽治疗缺血性心肌病患者急性心衰的短期疗效观察

Short-term efficacy of recombinant human brain natriuretic peptide in the treatment of acute heart failure in ischemic cardiomyopathy patients

目的观察重组人脑利钠肽治疗缺血性心肌病患者急性心力衰竭的短期疗效及其不良反应。方法入组患者均接受指南推荐的标准治疗,治疗组(n=25)在此基础上加用重组人脑利钠肽治疗,对照组(n=25)加用硝酸甘油。观察两组患者总有效率、心功能分级、住院病死率、住院时间、治疗后平均血压及不良反应。并分析用药前后射血分数情况。结果治疗组总有效率为92%,对照组总有效率为60%,治疗组较对照组疗效更佳(P<0.05)。治疗组NYHA分级、住院时间、住院病死率均较对照组下降(P<0.05)。结论重组人脑利钠肽对缺血性心肌病患者急性心衰时的早期心功能改善有益,不良反应发生率低。

Objective To evaluate the short-term efficacy and safety of recombinant human brain natriuretic peptide in the treatment of acute heart failure in ischemic cardiomyopathy patients. Methods Fifty patients received the recommended standard treatment. Among them 25 patients as the treatment group were administreted with recombinant human brain natriuretic peptide and other 25 as control group with nitroglycerin. To obseve the total effective, NYHA, hospital mortality, haspitalized time, mean blood pressure, and adverse reaction. Left ventricular ejection fraction was measured before and after treatment. Results The total effective rate was 92% in the treatment group, but 60% in control group（P〈0.05）. The NYHH hospitalized time and hospital mortality of the treatrment group was lower significantly than those of the control group（P〈0.05）. Conclusion Recombinant human brain natriuretic peptide can improve the heart function of ischemic cardiomyopathy patients in early period with less adverse reactions.